Advanced Hematologic Malignancies

Pipeline Programs

Companies

Clinical Trials

1 recruiting

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

4SCGermany - Planegg-Martinsried

1 program

4SC-202Phase 1/22 trials

Active Trials

NCT03278665Completed40Est. Feb 2022

NCT01344707Completed36Est. Mar 2015

Chia Tai TianQing Pharmaceutical GroupChina - Lianyungang

1 program

TQB2101 for InjectionPHASE_11 trial

Active Trials

NCT07113925Recruiting114Est. Jun 2028

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

2027

2028

4SC4SC-202

Chia Tai TianQing Pharmaceutical GroupTQB2101 for Injection

4SC4SC-202

Clinical Trials (3)

Total enrollment: 190 patients across 3 trials

NCT03278665 4SC4SC-202

4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy

Start: Sep 2017Est. completion: Feb 202240 patients

Phase 1/2Completed

NCT07113925 Chia Tai TianQing Pharmaceutical GroupTQB2101 for Injection

A Clinical Trial Evaluating TQB2101 in Subjects With Advanced Hematologic Malignancies

Start: Aug 2025Est. completion: Jun 2028114 patients

Phase 1Recruiting

NCT01344707 4SC4SC-202

Oral Histone Deacetylase Inhibitor 4SC-202 in Patients With Advanced Hematologic Malignancies (TOPAS)

Start: Mar 2011Est. completion: Mar 201536 patients

Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 190 patients

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.